Altana Pharma Extends Collaboration With Atugen Another Year

Feb 17, 2005

NEW YORK, Feb. 17 (GenomeWeb News) - Atugen has extended by one year its non-exclusive target validation and license agreement with Altana Pharma, the company said yesterday.

The extended deal, originally signed in 2001, calls for Atugen to continue validating potential targets supplied by Altana. The agreement provides a license to Altana's gene-silencing and oligonucleotide-delivery technologies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

DNA Tests Considered to Verify Relatedness at Border

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

First of 'Right to Try'

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

This Week in Nature

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

How Old Were They?

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.

Main menu